Russell Hirsch , MD, PhD

Director

Prospect Ventures
Palo Alto, CA

Russel Hirsch, M.D., Ph.D., is a managing director of Prospect Venture Partners. Dr. Hirsch co-founded Prospect Venture Partners II and II, as dedicated life science funds with more than $1 billion in capital under management. Prospect is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prior to Prospect, Dr. Hirsch served as a Venture Partner from 1993 to 1994 and later a General Partner from 1995 to 2000 at the Health Care and Technology Group, Mayfield. At Mayfield, Dr. Hirsch helped manage the investment activities in the biotechnology and medical device sectors. He participated int he incubation of both Millennium Pharmaceuticals (acquired by Takeda) and Intuitive Surgical Devices (NASDAQ:ISRG). Previously, Dr. Hirsch was engaged in biomedical research at the University of California San Francisco. His work which focused on aspects of hepatitis B viral replication was published in a variety of medical journals such as Nature. Dr. Hirsch is serves or has served on the Board of Directors of Intuitive Surgical (NASDAQ: ISRG), Hansen Medical (NASDAQ: HNSN), Opus Medical (NASDAQ: ARTC), Orquest (NASDAQ: JNJ), AVEO Pharmaceuticals (NASDAQ: AVEO), Visiogen (NYSE: ABT acquired), Baxano, Dfine, SentreHEART, Portola Pharmaceuticals and several other privately-held companies. Additionally, he is Vice Chairman of the BOD of Interplast and on the Genetics Advisory Council of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. Dr. Hirsch received his M.D. and Ph.D. in Biochemistry from the University of California San Francisco as well as his B.A. degree in Chemistry from the University of Chicago.